潜在抗肝纤维化药物与靶点相关信号通路研究进展  

Research advances in signaling pathways associated with potential anti-liver fibrosis drugs and targets

作　　者：周鑫 王智 何雪茹[1,2] 付裕豪 荀雪姣 李颖 董占军[2] ZHOU Xin;WANG Zhi;HE Xueru;FU Yuhao;XUN Xuejiao;LI Ying;DONG Zhanjun(Graduate School of Hebei Medical University,Shijiazhuang 050017,China;Department of Pharmacy,Hebei General Hospital,Shijiazhuang 050057,China)

机构地区：[1]河北医科大学研究生学院,石家庄050017 [2]河北省人民医院药学部,石家庄050057

出　　处：《临床肝胆病杂志》2023年第12期2932-2941,共10页Journal of Clinical Hepatology

基　　金：河北省卫健委课题(20210037)。

摘　　要：肝纤维化是慢性肝病进展为肝硬化甚至肝癌的关键一步。近年来,大量研究表明了干预肝纤维化进程的必要性,各种抗肝纤维化药物及活性成分相继被发现。非编码RNA在调解肝纤维化进程中也发挥重要作用,寻找能够调节信号通路介导的上游非编码RNA可以为抗肝纤维化治疗提供新的见解。本文分别介绍了TGF-β、Wnt/β-catenin、PI3K/Akt/mTOR、NF-κB、Hippo和MAPK信号通路介导的肝纤维化进程,并列举了各信号通路中最新的抗肝纤维化药物或活性成分以及相关非编码RNA介导的抗肝纤维化靶点与药物的研究进展,以期为抗肝纤维化提供新的研究思路和治疗方法。Liver fibrosis is a key step in the progression of chronic liver diseases to liver cirrhosis and even liver cancer.In recent years,a large number of studies have shown the necessity of intervening in the process of liver fibrosis,and various antiliver fibrosis drugs and active ingredients have been discovered.Non-coding RNAs also play an important role in the process of liver fibrosis,and searching for upstream non-coding RNAs that can regulate signaling pathways can provide new insights for anti-liver fibrosis treatment.This article introduces the process of liver fibrosis mediated by the TGF-β,Wnt/β-catenin,PI3K/Akt/mTOR,NF-κβ,Hippo,and MAPK signaling pathways,lists the latest anti-liver fibrosis drugs or active components in each signaling pathway,and summarizes the research advances in anti-liver fibrosis targets and drugs mediated by related non-coding RNAs,so as to provide new research ideas and treatment methods for anti-liver fibrosis treatment.

关 键 词：肝纤维化 信号传导 药用制剂 RNA 未翻译 

分 类 号：R575.2[医药卫生—消化系统]